Research Article
Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus
Table 1
Comparison of clinical characteristics between quiescent and active SLE patients.
| | | SLE patients | Test value | value | | | Quiescent disease () | Active disease () |
| | Number of males/females | 6/28 | 9/64 | 0.544 | 0.461 | | Age (years), median (range) | 30 (21 to 62) | 28 (18 to 62) | 15.919 | 0.998 | | SLEDAI, median (range) | 2 (0 to 4) | 11 (5 to 30) | 10.808 | | | Seizure, | 0 (0%) | 17 (23.3%) | 9.413 | | | ANA (U/mL), median (range) | 175.0 (91.4 to 873.7) | 166.6 (45.8 to 865.8) | −0.295 | 0.768 | | Anti-dsDNA (U/mL), median (range) | 53.9 (31.6 to 76.5) | 76.4 (25.6 to 717.5) | 3.711 | | | Anti-ribosomal P antibodies, | 8 (24%) | 26 (36%) | 1.563 | 0.211 | | SSA, | 17 (50%) | 38 (52%) | 0.039 | 0.843 | | SSB, | 8 (24%) | 14 (19%) | 0.269 | 0.604 | | C3 (g/L), median (range) | 0.78 (0.28 to 1.53) | 0.34 (0.13 to 1.08) | −8.134 | | | C4 (g/L), median (range) | 0.16 (0.05 to 0.28) | 0.06 (0.01 to 0.33) | −3.817 | | | Number with/without treatment | 31/3 | 54/19 | | | | Users of prednisone (%) | 20 (59%) | 42 (58%) | 0.016 | 0.900 | | Dose (mg/day), median (range) | 10 (2.5 to 50) | 7.5 (2.5 to 100) | | | | Users of hydroxychloroquine (%) | 20 (59%) | 35 (48%) | 1.099 | 0.295 | | Dose (mg/day), median (range) | 400 (150 to 400) | 400 (200 to 400) | | |
|
|
